Keunen et al. reported that, in a rat-patient-derived xenograft model, bevacizumab treatment resulted in a decrease in tumor volume and tumor blood flow, but a 68% increase in infiltrating cells, which was associated with the enhanced expression of HIF-1 and activation of the PI3K pathway and Wnt-signaling pathway [121]. This evidence concerns the gene HIF1A and neoplasm.